SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-20-001175
Filing Date
2020-01-16
Accepted
2020-01-16 14:47:06
Documents
5
Period of Report
2020-01-16

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER f6k011620b_biondvaxpharma.htm 6-K 11248
2 AMENDMENT NO. 1 TO ADS WARRANT AGENT AGREEMENT f6k011620bex99-1_biondvax.htm EX-99.1 14945
3 NOTICE TO HOLDERS OF WARRANTS f6k011620bex99-2_biondvax.htm EX-99.2 9971
4 PRESS RELEASE DATED JANUARY 16, 2020 f6k011620bex99-3_biondvax.htm EX-99.3 7567
5 GRAPHIC ex99-3_001.jpg GRAPHIC 23768
  Complete submission text file 0001213900-20-001175.txt   77584
Mailing Address 14 EINSTEIN ST. NES-ZIONA L3 74036
Business Address 14 EINSTEIN ST. NES-ZIONA L3 74036 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-37353 | Film No.: 20530385
SIC: 2836 Biological Products, (No Diagnostic Substances)